Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Table 1 Clinical inputs parameter estimates

Parameter	Annual probabilities
Parameter	Non-prophylaxis	Source	Palivizumab	Source
Probability of hospital admission due RSV infection
Total population	4.10%	[14]	1.30%	[14]
Subgroup A	18.40%	[33]	9.50%	[33]
Subgroup B	10.60%		3.60%
Subgroup C	10.20%		2.90%
Probability of emergency visits prior to hospital admission
	17.80%	[14]	17.80%	[14]
Probability of death related to hospital admission
	2.33%	[3]	2.33%	[3]
Probability of additional hospitalizations due to new RSV infection
	2.47%	[14]	2.47%	[14]
Probability of recurrent wheezing in hospitalized patients.
Year 2	41.43%	[15]	18.43%	[15]
Year 3	29.27%		11.05%
Year 4	18.55%		6.12%
Year 5	15.00%		4.39%
Year 6	12.39%		3.25%
Probability of recurrent wheeze in no-hospitalized patients
Year 2	12.09%	[15]	5.38%	[15]
Year 3	15.36%		5.80%
Year 4	12.57%		4.15%
Year 5	9.31%		2.73%
Year 6	9.66%		2.53%

Subgroup A includes preterm infants with 2 major risk factors and 2 minor risk factors; subgroup B, 2 major risk factors and 1 minor risk factors; subgroup C, 2 major risk factors [33]
Major factors: chronological age less than 10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance. Minor factors: mother smoking during pregnancy and male gender

ISSN: 1471-2334